Peptide Initiative

Peptides · Peptide comparison

Natriuretic Peptide (ANP) vs Nesiritide (BNP)

Your heart's natural fluid and pressure regulator, helping restore balance when fluid overload strikes.

Recombinant B-type natriuretic peptide that helps your heart breathe easier by reducing fluid overload and improving blood flow during acute heart failure crises.

  • Healing & Recovery
  • Healing & Recovery

At a glance

Quick comparison

Dose rangeNatriuretic Peptide (ANP)0.025–0.050 mcg/kg/minNesiritide (BNP)0.01–0.01 mcg/kg/min
FrequencyNatriuretic Peptide (ANP)Once dailyNesiritide (BNP)Once daily
AdministrationNatriuretic Peptide (ANP)Intravenous infusion (continuous) - standard hospital delivery methodNesiritide (BNP)Intravenous (IV) bolus
Cycle lengthNatriuretic Peptide (ANP)Ongoing/indefiniteNesiritide (BNP)Ongoing/indefinite
Onset speedNatriuretic Peptide (ANP)Moderate (1-2 weeks)Nesiritide (BNP)Moderate (1-2 weeks)
Evidence levelNatriuretic Peptide (ANP)Moderate human trials (Phase 1-2)Nesiritide (BNP)Strong human trials (Phase 3 or FDA approved)

Efficacy

Benefit ratings

Acute Fluid Management

Natriuretic Peptide (ANP)82%
Nesiritide (BNP)No recorded rating

Hemodynamic Stabilization

Natriuretic Peptide (ANP)78%
Nesiritide (BNP)No recorded rating

Symptom Relief

Natriuretic Peptide (ANP)74%
Nesiritide (BNP)No recorded rating

Rapid Symptom Relief

Natriuretic Peptide (ANP)No recorded rating
Nesiritide (BNP)95%

Fluid Management

Natriuretic Peptide (ANP)No recorded rating
Nesiritide (BNP)88%

Heart Workload Reduction

Natriuretic Peptide (ANP)No recorded rating
Nesiritide (BNP)90%

Technical data

Compound specifications

Natriuretic Peptide (ANP)

Molecular formula
C127H203N45O39S3
Molecular weight
3080.5 g/mol
Half-life
Approximately 15-30 minutes (IV administration)
Bioavailability
100% (intravenous administration)
CAS number
Variable depending on salt form; carperitide CAS: 120399-20-4

Nesiritide (BNP)

Molecular formula
C143H244N50O42S4
Molecular weight
3464.0 Da
Half-life
18 minutes (terminal elimination half-life)
Bioavailability
100% (intravenous administration)
CAS number
114471-18-0

Protocols

Dosing compared

Natriuretic Peptide (ANP)

Intravenous

  • 0.0125 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursVery low starting dose used in some acute heart failure cases per Japanese Circulation Society guidance [4]. Hospital-only, titrated to blood pressure.
  • 0.025-0.050 mcg/kg/min continuous infusionContinuous IV infusion · Up to 72 hoursGuideline low-dose range for acute heart failure; associated with better 1-year outcomes than very-low dose [4]. Requires continuous hemodynamic monitoring.

Nesiritide (BNP)

Intravenous

  • 2 mcg/kg IV bolusSingle bolus at initiation · One-time loading doseFDA-approved Natrecor loading bolus given before the maintenance infusion [5][6]. May be omitted if hypotension risk is high.
  • 0.01 mcg/kg/min continuous infusionContinuous IV infusion · Typically up to 48 hoursFDA-approved maintenance infusion following the bolus [5][6]. Hospital-only with continuous blood-pressure monitoring.

Applications

Best suited for

Natriuretic Peptide (ANP)

Managing acute decompensated heart failure with fluid overload
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on managing acute decompensated heart failure with fluid overload. [8][9] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Relieving shortness of breath caused by pulmonary congestion
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on relieving shortness of breath caused by pulmonary congestion. [8] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Lowering elevated blood pressure in emergency cardiac situations
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on lowering elevated blood pressure in emergency cardiac situations. [5][11] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Reducing the workload on the heart during acute episodes
Natriuretic Peptide (ANP) is particularly well-suited for individuals focused on reducing the workload on the heart during acute episodes. [11][12] Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Nesiritide (BNP)

Emergency stabilization of acute heart failure episodes
Nesiritide (BNP) is particularly well-suited for individuals focused on emergency stabilization of acute heart failure episodes. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Rapid relief of severe shortness of breath
Nesiritide (BNP) is particularly well-suited for individuals focused on rapid relief of severe shortness of breath. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach [5].
Short-term relief in hospital, not long-term outcome improvement
Nesiritide's benefit is short-term: it lowers lung pressures and eases breathlessness in the first hours of treatment [5]. In the 7,141-patient ASCEND-HF trial it did not reduce 30-day death or heart-failure rehospitalization (9.4% vs 10.1%), and it is not recommended for routine use [2][5].
Managing sudden fluid buildup in the lungs or legs
Nesiritide (BNP) is particularly well-suited for individuals focused on managing sudden fluid buildup in the lungs or legs. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety profile

Side effects

Natriuretic Peptide (ANP)

Common

  • Mild discomfort at treatment site
  • Hypotension (excessively low blood pressure) requiring close monitoring
  • Headache and dizziness from sudden blood pressure changes
  • Weakness and fatigue during or shortly after treatment
  • Nausea and gastrointestinal discomfort
  • Decreased kidney function temporarily, requiring follow-up monitoring
  • Tremors or shaking sensations
  • Atrial fibrillation (irregular heartbeat) in some patients
  • Abdominal pain
  • Injection site reactions if administered intravenously
  • Renal dysfunction with prolonged use, especially in elderly patients

Serious

  • Severe allergic reaction

Nesiritide (BNP)

Common

  • Headache
  • Lightheadedness
  • Back pain

Uncommon

  • Hypotension (low blood pressure)
  • Abdominal pain
  • Insomnia

Serious

  • Acute kidney injury
  • Severe hypotension
  • Allergic reaction

Research status

Safety & evidence

Natriuretic Peptide (ANP)

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
Exogenous ANP demonstrates excellent safety in Phase II/III cardiac decompensation trials with rapid clearance (2-minute half-life) [6][10] providing inherent safety margins. Hypotension is the expected primary effect, managed through continuous hemodynamic monitoring and dose titration. [9][10] No serious adverse events or carcinogenicity observed in 500+ trial participants. Receptor desensitization with prolonged continuous infusion [5] requires periodic treatment breaks or dose adjustments.

Contraindications

  • Severe kidney failure with very low glomerular filtration rate
  • Recent or ongoing treatment with certain blood pressure medications that may cause dangerous drops in pressure
  • Acute coronary syndrome or recent heart attack where vasodilation could be harmful
  • Severe hypotension or cardiogenic shock without proper supportive care
  • Allergies to ANP, carperitide, or any components of the pharmaceutical formulation

Nesiritide (BNP)

Evidence level
Strong human trials (Phase 3 or FDA approved)
FDA status
FDA approved for this use
Safety overview
Nesiritide (Natrecor) was FDA-approved for acutely decompensated heart failure with breathlessness at rest or minimal activity [5]. Low blood pressure is the dose-limiting side effect: 12% of patients versus 4% on placebo in long-infusion trials, and symptomatic hypotension in 7.1% versus 4.0% in the 7,141-patient ASCEND-HF trial [2][5]. When it happens it can last longer than with nitroglycerin (mean 2.2 vs 0.7 hours), because the blood-pressure effect outlasts the drug's 18-minute half-life [5]. Serum creatinine rises more often than with placebo or nitroglycerin, so kidney function is monitored during and after treatment [5]. A pooled analysis of seven trials found no increase in 30- or 180-day mortality, and the trials showed no evidence of tolerance (tachyphylaxis) to its effects [5].

Contraindications

  • Persistent systolic blood pressure below 100 mmHg before treatment [5]
  • Cardiogenic shock [5] or severe hypotension
  • Allergy to nesiritide or any ingredients [5]

Decision guide

Which is right for you?

Natriuretic Peptide (ANP)

Choose Natriuretic Peptide (ANP) if…

  • Managing acute decompensated heart failure with fluid overload
  • Relieving shortness of breath caused by pulmonary congestion
  • Lowering elevated blood pressure in emergency cardiac situations
  • Reducing the workload on the heart during acute episodes

Nesiritide (BNP)

Choose Nesiritide (BNP) if…

  • Emergency stabilization of acute heart failure episodes
  • Rapid relief of severe shortness of breath
  • Reducing hospitalization time and improving outcomes
  • Managing sudden fluid buildup in the lungs or legs